(329) Mannosylated Lipid Nanoparticles for Targeted in Vivo mRNA Delivery
Introduction: Lipid nanoparticle (LNP)-based mRNA vaccines have shown great success, especially against COVID-19, by encoding antigenic proteins that stimulate antigen-presenting cells (APCs), triggering immune responses in B and T cells. However, their effectiveness is often limited by low accumulation in APCs like dendritic cells (DCs), requiring high doses for optimal responses. This study synthesized cholesterol-derived mannopolypeptides (CPSM) to co-assemble into mannosylated LNPs, enhancing targeting and mRNA delivery efficacy.
Learning Objectives:
Demonstrate that Cholesterol derivatives stabilize LNPs reducing drug leakage
Mannose moieties on biodegradable polymer enable receptor-mediated targeting of APCs
Mannosylated LNPs enable lymph node and APC-targeting
